Healthcare -
Biotechnology - NASDAQ - US
$ 0.2121
-1.16 %
$ 36.8 M
Market Cap
-1.12
P/E
1. INTRINSIC VALUE
FINANCIALS
Balance Sheet
X4 Pharmaceuticals, Inc.
| Current Assets | 112 M |
| Cash & Short-Term Investments | 102 M |
| Receivables | 1.71 M |
| Other Current Assets | 8.4 M |
| Non-Current Assets | 34.3 M |
| Long-Term Investments | 0 |
| PP&E | 4.84 M |
| Other Non-Current Assets | 29.4 M |
| Current Liabilities | 32.9 M |
| Accounts Payable | 8.62 M |
| Short-Term Debt | 1.25 M |
| Other Current Liabilities | 23 M |
| Non-Current Liabilities | 91.4 M |
| Long-Term Debt | 2.82 M |
| Other Non-Current Liabilities | 88.6 M |
EFFICIENCY
Earnings Waterfall
X4 Pharmaceuticals, Inc.
| Revenue | 2.56 M |
| Cost Of Revenue | 797 K |
| Gross Profit | 1.76 M |
| Operating Expenses | 38.2 M |
| Operating Income | -36.4 M |
| Other Expenses | 1.05 M |
| Net Income | -37.4 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
X4 Pharmaceuticals, Inc.
| Net Income | -37.4 M |
| Depreciation & Amortization | 796 K |
| Capital Expenditures | -326 K |
| Stock-Based Compensation | 8.2 M |
| Change in Working Capital | 0 |
| Others | -102 M |
| Free Cash Flow | -131 M |
Wall Street Analysts Price Targets
X4 Pharmaceuticals, Inc.
Wall Street analysts predict an average 1-year price target for XFOR of $3.67 , with forecasts ranging from
a
low of
$3 to a high of $5 .
XFOR Lowest Price Target
Wall Street Target
3 USD
1314.43%
XFOR Average Price Target
Wall Street Target
3.67 USD
1628.74%
XFOR Highest Price Target
Wall Street Target
5 USD
2257.38%
4. DIVIDEND
ANALYSIS
XFOR does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
X4 Pharmaceuticals, Inc.
Sold
0-3 MONTHS
97.3 K USD 5
3-6 MONTHS
12.6 K USD 1
6-9 MONTHS
366 K USD 5
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
4.6 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
14.7 K USD 1
9-12 MONTHS
7. News
X4 Pharmaceuticals, Inc. (XFOR) Q4 2024 Earnings Call Transcript
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR ) Q4 2024 Earnings Conference Call March 25, 2025 8:30 AM ET Company Participants Daniel Ferry - IR, LifeSci Advisors Paula Ragan - CEO Adam Mostafa - CFO Christophe Arbet-Engels - Chief Medical Officer Mark Baldry - CCO Conference Call Participants Stephen Willey - Stifel Ed Tenthoff - Piper Sandler Ayan Hussein - Cantor Fitzgerald Doug MacPherson - H.C. Wainwright David Bautz - Zacks Small-Cap Research Operator Greetings, and welcome to the X4 Pharmaceuticals Fourth Quarter and Full Year 2024 Financial and Operating Results Conference Call.
seekingalpha.com
- 3 weeks ago
X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Phase 3 4WARD trial in chronic neutropenia now activated at ~90% of targeted trial sites; full enrollment expected in 3Q or 4Q 2025; top-line data anticipated in 2H 2026
globenewswire.com
- 3 weeks ago
X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025
BOSTON, March 11, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2024 and provide corporate updates on Tuesday, March 25, 2025.
globenewswire.com
- 1 month ago
X4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI® (mavorixafor) in WHIM Syndrome in Select Middle East Countries
Agreement covers Saudi Arabia, United Arab Emirates, Qatar, Oman, Kuwait, Bahrain, and Egypt Agreement covers Saudi Arabia, United Arab Emirates, Qatar, Oman, Kuwait, Bahrain, and Egypt
globenewswire.com
- 2 months ago
X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia
Full enrollment in ongoing global, pivotal Phase 3 clinical trial in chronic neutropenia on track for mid-2025
globenewswire.com
- 2 months ago
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on January 31, 2025, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 130,117 shares of X4's common stock. These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by X4's Compensation Committee of the Board of Directors.
globenewswire.com
- 2 months ago
X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor for the Treatment of WHIM Syndrome
Submission supported by positive results from global, Phase 3 4WHIM clinical trial; U.S. regulatory approval in WHIM syndrome granted in 2024 Decision on MAA expected in 1H 2026 BOSTON, Jan. 24, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that its Marketing Authorization Application (MAA) for mavorixafor for the treatment of WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis), a rare primary immunodeficiency, has been validated for review and is now under evaluation with the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP). The EMA previously granted orphan designation to mavorixafor in WHIM syndrome.
globenewswire.com
- 2 months ago
X4 Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand
X4 to receive a €28.5 million upfront payment and up to €226 million in potential regulatory and commercial milestone payments in addition to tiered, double-digit royalties up to the mid-twenties
globenewswire.com
- 3 months ago
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Dec. 03, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on December 2, 2024, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 396,824 shares of X4's common stock. These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by X4's Compensation Committee of the Board of Directors.
globenewswire.com
- 4 months ago
X4 Pharmaceuticals to Participate in the Stifel 2024 Healthcare Conference
BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management will participate in the Stifel 2024 Healthcare Conference, taking place in New York, NY on November 18-19, 2024.
globenewswire.com
- 5 months ago
X4 Pharmaceuticals, Inc. (XFOR) Q3 2024 Earnings Call Transcript
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR ) Q3 2024 Earnings Conference Call November 13, 2024 8:00 AM ET Company Participants Daniel Ferry - IR, LifeSci Advisors Paula Ragan - CEO Christophe Arbet-Engels - Chief Medical Officer Mark Baldry - CCO Conference Call Participants Kristen Kluska - Cantor Edward Tenthoff - Piper Sandler Swayampakula Ramakanth - H.C. Wainwright Stephen Willey - Stifel David Bautz - Zacks Operator Greetings, and welcome to the X4 Pharmaceuticals Call and Webcast.
seekingalpha.com
- 5 months ago
X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Positive results from completed Phase 2 study of mavorixafor in chronic neutropenia (CN) announced today Pivotal Phase 3 trial of mavorixafor in CN on track to fully enroll in mid-2025 U.S. launch of XOLREMDI® (mavorixafor) in WHIM underway; submission of Marketing Authorization Application (MAA) to European Medicines Agency (EMA) expected by early 2025 Conference call and webcast today at 8:00 a.m. ET BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today reported financial results for the third quarter ended September 30, 2024 and highlighted recent and key upcoming expected milestones.
globenewswire.com
- 5 months ago
8. Profile
Summary
X4 Pharmaceuticals, Inc. XFOR
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 36.8 M
Dividend Yield
0.00%
Description
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.
Contact
61 North Beacon Street, Boston, MA, 02134
https://www.x4pharma.com
IPO
Date
Nov. 16, 2017
Employees
143
Officers
Dr. Paula Ragan Ph.D.
Chief Executive Officer, President & Director
Dr. Mary DiBiase Ph.D.
Chief Operating Officer
Dr. Robert David Arbeit
Senior Vice President of Clinical Development and Translational Research
Dr. Christophe Arbet-Engels M.B.A., M.D., Ph.D.
Chief Medical Officer
Ms. Natasha Thoren Esq.
Vice President, General Counsel & Compliance Officer
Dr. Arthur Taveras Ph.D.
Chief Scientific Officer
Dr. Renato T. Skerlj Ph.D.
Founder
Mr. Adam S. Mostafa
Chief Financial Officer, Treasurer & Corporate Secretary
Dr. Richard Peters M.D., Ph.D.
Chairman of the Board & Founder
Dr. Keith T. Flaherty M.D.
Founder & Member of Corporate Advisory Board